Patents by Inventor Hannah Ceuleers

Hannah Ceuleers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases
    Patent number: 11638712
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: May 2, 2023
    Assignee: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk
  • BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES
    Publication number: 20220023320
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk
  • Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases
    Patent number: 11166967
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: November 9, 2021
    Assignee: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk
  • BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES
    Publication number: 20190175629
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Application
    Filed: May 18, 2017
    Publication date: June 13, 2019
    Applicant: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk